MILNE GEORGE M JR sold $831K of AMLX
MILNE GEORGE M JR sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $27.70 ($0.83M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this insider transaction, providing new data for traders monitoring insider activity.
Market read
A modest insider sell by a director may cause slight short‑term price pressure but is unlikely to move the broader market.
What to watch
The 10b5‑1 plan pre‑arranges sales, reducing the informational value of the transaction.
Background
Amylyx Pharmaceuticals (AMLX) is a US‑listed biotech focused on rare neurological disorders.
Ticker impact
Director George Milne sold 30,000 shares for $830,904 via a 10b5‑1 plan, reducing his stake to 782,881 shares.
likely downward pressure as the market prices the insider sell.
A director off‑loading $0.8 M of stock signals potential concern, but the amount is small relative to market cap.
Market effects
Minimal impact on the biotech sector; typical insider sales are routine.
No broader regional effect.
Limited to AMLX investors.
Counterpoint
The sale may be purely portfolio rebalancing; price could remain stable.
Key entities
- companyAmylyx Pharmaceuticals, Inc.
Issuer of the Form 4 filing.
- personGeorge Milne
Director and insider who sold shares.
